Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

The drug is already approved in the EU to treat certain cases of non-small lung cancer, as well as oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. Mark ...

Welcome to the Revolution Medicines Q1 2025 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...

NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] for details. The recommendations in this guidance ...

Q1 2025 Earnings Call Transcript May 8, 2025 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Stage 3 lung cancer is considered locally advanced with spread in the region near the site. Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, ...

aDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA bDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...